The Hamburg biotech company Evotec
implements a beta cell program for the treatment of
For the time being, diabetes patients go it alone again. The enterprise
have worldwide rights to develop and market the im
Under a cooperation agreement with Sanofi
developed program, Evotec said on Wednesday
With. The MDax listed share preregistered
almost one percent too.
Evotec and Sanofi have been developing the project together since 2015.
The program produces human beta cells that
Normalize blood sugar levels through insulin delivery and thus
represent a possible alternative to the common insulin syringe.
Evotec sees this as a “potentially revolutionary treatment option”
and is now looking for new strategic options for the future
Development and marketing. The possibility for a partnership
will also be checked, it said. Sanofi has been pulling himself
some time back from diabetes research / kro / fba
ISIN DE0005664809
AXC0084 2020-04-22 / 08: 41
Copyright dpa-AFX Wirtschaftsnachrichten GmbH. All rights reserved. Redistribution, republication or permanent storage without the express prior consent of dpa-AFX is not permitted.
.
